CN102427726B - 丙型肝炎的稠环抑制剂 - Google Patents

丙型肝炎的稠环抑制剂 Download PDF

Info

Publication number
CN102427726B
CN102427726B CN201080021446.2A CN201080021446A CN102427726B CN 102427726 B CN102427726 B CN 102427726B CN 201080021446 A CN201080021446 A CN 201080021446A CN 102427726 B CN102427726 B CN 102427726B
Authority
CN
China
Prior art keywords
heterocycle
alkyl
aryl
heteroaryl
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201080021446.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN102427726A (zh
Inventor
L·李
M·钟
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Presidio Pharmaceuticals Inc
Original Assignee
Presidio Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Presidio Pharmaceuticals Inc filed Critical Presidio Pharmaceuticals Inc
Publication of CN102427726A publication Critical patent/CN102427726A/zh
Application granted granted Critical
Publication of CN102427726B publication Critical patent/CN102427726B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
CN201080021446.2A 2009-03-27 2010-03-25 丙型肝炎的稠环抑制剂 Expired - Fee Related CN102427726B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US16434209P 2009-03-27 2009-03-27
US61/164,342 2009-03-27
US21488309P 2009-04-28 2009-04-28
US61/214,883 2009-04-28
PCT/US2010/028730 WO2010111534A1 (en) 2009-03-27 2010-03-25 Fused ring inhibitors of hepatitis c

Publications (2)

Publication Number Publication Date
CN102427726A CN102427726A (zh) 2012-04-25
CN102427726B true CN102427726B (zh) 2014-10-08

Family

ID=42781523

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201080021446.2A Expired - Fee Related CN102427726B (zh) 2009-03-27 2010-03-25 丙型肝炎的稠环抑制剂

Country Status (19)

Country Link
US (1) US9150554B2 (enExample)
EP (1) EP2410843A4 (enExample)
JP (1) JP5735482B2 (enExample)
KR (1) KR20110131312A (enExample)
CN (1) CN102427726B (enExample)
AR (1) AR076164A1 (enExample)
AU (1) AU2010229795A1 (enExample)
BR (1) BRPI1012282A2 (enExample)
CA (1) CA2755658A1 (enExample)
CL (1) CL2011002377A1 (enExample)
CO (1) CO6450600A2 (enExample)
EA (1) EA201190224A1 (enExample)
IL (1) IL215202A0 (enExample)
MX (1) MX2011010132A (enExample)
PE (1) PE20120773A1 (enExample)
SG (1) SG174883A1 (enExample)
TW (1) TW201038560A (enExample)
WO (1) WO2010111534A1 (enExample)
ZA (1) ZA201107753B (enExample)

Families Citing this family (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2011006332A (es) 2008-12-23 2011-06-27 Abbott Lab Compuestos antivirales.
EP2367823A1 (en) 2008-12-23 2011-09-28 Abbott Laboratories Anti-viral compounds
US8314135B2 (en) 2009-02-09 2012-11-20 Enanta Pharmaceuticals, Inc. Linked dibenzimidazole antivirals
US8242156B2 (en) 2009-02-17 2012-08-14 Enanta Pharmaceuticals, Inc. Linked dibenzimidazole derivatives
US8188132B2 (en) 2009-02-17 2012-05-29 Enanta Pharmaceuticals, Inc. Linked dibenzimidazole derivatives
US8394968B2 (en) 2009-02-17 2013-03-12 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9765087B2 (en) 2009-02-27 2017-09-19 Enanta Pharmaceuticals, Inc. Benzimidazole derivatives
US8673954B2 (en) 2009-02-27 2014-03-18 Enanta Pharmaceuticals, Inc. Benzimidazole derivatives
US8101643B2 (en) 2009-02-27 2012-01-24 Enanta Pharmaceuticals, Inc. Benzimidazole derivatives
US8507522B2 (en) 2009-03-06 2013-08-13 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
MX2011010132A (es) 2009-03-27 2011-10-14 Presidio Pharmaceuticals Inc Inhibidores de anillo fusionado de hepatitis c.
US20190127365A1 (en) 2017-11-01 2019-05-02 Merck Sharp & Dohme Corp. Inhibitors of hepatitis c virus replication
CN109651342A (zh) 2009-03-27 2019-04-19 默沙东公司 丙型肝炎病毒复制的抑制剂
US8796466B2 (en) 2009-03-30 2014-08-05 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
TW201038559A (en) 2009-04-09 2010-11-01 Bristol Myers Squibb Co Hepatitis C virus inhibitors
US8143414B2 (en) 2009-04-13 2012-03-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
SG175144A1 (en) 2009-04-15 2011-11-28 Abbott Lab Anti-viral compounds
EP2430015B1 (en) * 2009-05-12 2015-06-17 Merck Sharp & Dohme Corp. Fused tricyclic compounds useful for the treatment of viral diseases
BRPI1010795B1 (pt) 2009-05-13 2018-12-11 Gilead Pharmasset Llc compostos antivirais, seu uso e composição farmacêutica compreendendo os mesmos
US8138215B2 (en) 2009-05-29 2012-03-20 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8211928B2 (en) 2009-05-29 2012-07-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8716454B2 (en) 2009-06-11 2014-05-06 Abbvie Inc. Solid compositions
US8937150B2 (en) 2009-06-11 2015-01-20 Abbvie Inc. Anti-viral compounds
US9394279B2 (en) 2009-06-11 2016-07-19 Abbvie Inc. Anti-viral compounds
PE20110679A1 (es) 2009-06-11 2011-10-20 Abbvie Bahamas Ltd Derivados de (4-tert-butilfenil)pirrolidin-2,5-difenil como inhibidores del hcv
US8221737B2 (en) 2009-06-16 2012-07-17 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8609648B2 (en) 2009-07-02 2013-12-17 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
CN102656160A (zh) 2009-07-16 2012-09-05 顶点制药公司 用于治疗或预防黄病毒感染的苯并咪唑类似物
NZ598942A (en) 2009-07-27 2014-02-28 Gilead Sciences Inc Fused heterocyclic compounds as ion channel modulators
CN102480971B (zh) 2009-09-04 2014-11-26 杨森制药公司 化合物
US9156818B2 (en) 2009-09-11 2015-10-13 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8927709B2 (en) 2009-09-11 2015-01-06 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8822700B2 (en) 2009-09-11 2014-09-02 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8703938B2 (en) 2009-09-11 2014-04-22 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8815928B2 (en) 2009-09-11 2014-08-26 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8759332B2 (en) 2009-09-11 2014-06-24 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US20110269956A1 (en) * 2009-11-11 2011-11-03 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US20110274648A1 (en) 2009-11-11 2011-11-10 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US20110281910A1 (en) 2009-11-12 2011-11-17 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
EP2512480A4 (en) 2009-12-14 2013-05-15 Enanta Pharm Inc HEPATITIS C-VIRUS HEMMER
US8377980B2 (en) 2009-12-16 2013-02-19 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US20110152246A1 (en) * 2009-12-18 2011-06-23 Intermune, Inc. Novel inhibitors of hepatitis c virus replication
US8362020B2 (en) 2009-12-30 2013-01-29 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8933110B2 (en) 2010-01-25 2015-01-13 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
PE20130244A1 (es) 2010-01-25 2013-03-10 Enanta Pharm Inc Inhibidores del virus de la hepatitis c
US8178531B2 (en) 2010-02-23 2012-05-15 Enanta Pharmaceuticals, Inc. Antiviral agents
US8623814B2 (en) 2010-02-23 2014-01-07 Enanta Pharmaceuticals, Inc. Antiviral agents
BR112012022311A2 (pt) 2010-03-04 2016-08-23 Enanta Pharm Inc agentes farmacêuticos de combinação como inibidores da replicação de hcv.
MX2012010918A (es) 2010-03-24 2013-01-18 Vertex Pharma Analogos para el tratamiento o prevencion de infecciones por flavivirus.
EP2555622A4 (en) 2010-04-09 2013-09-18 Enanta Pharm Inc HEPATITIS C-VIRUS HEMMER
EP2575819A4 (en) 2010-06-04 2013-11-27 Enanta Pharm Inc INHIBITORS OF HEPATITIS C VIRUS
NZ605440A (en) 2010-06-10 2014-05-30 Abbvie Bahamas Ltd Solid compositions comprising an hcv inhibitor
CN103096977B (zh) 2010-07-02 2017-02-15 吉利德科学公司 作为离子通道调节剂的稠杂环化合物
WO2012003642A1 (en) * 2010-07-09 2012-01-12 Merck Sharp & Dohme Corp. Fused tricyclic compounds and use thereof for treating viral diseases
AU2011286276A1 (en) * 2010-07-26 2013-01-24 Merck Sharp & Dohme Corp. Substituted biphenylene compounds and methods of use thereof for the treatment of viral diseases
US8697704B2 (en) 2010-08-12 2014-04-15 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8999967B2 (en) 2010-09-29 2015-04-07 Presidio Pharmaceuticals, Inc. Tricyclic fused ring inhibitors of hepatitis C
CA2812779A1 (en) 2010-09-29 2012-04-19 Merck Sharp & Dohme Corp. Fused tetracycle derivatives and methods of use thereof for the treatment of viral diseases
SG10201509456SA (en) 2010-11-17 2015-12-30 Gilead Pharmasset Llc Antiviral compounds
RU2452735C1 (ru) 2010-11-30 2012-06-10 Александр Васильевич Иващенко Замещенные азолы, противовирусный активный компонент, фармацевтическая композиция, способ получения и применения
US8552047B2 (en) 2011-02-07 2013-10-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2012122716A1 (en) * 2011-03-17 2012-09-20 Merck Sharp & Dohme Corp. Tetracyclic xanthene derivatives and methods of use thereof for treatment of viral diseases
TWI577670B (zh) 2011-05-10 2017-04-11 基利科學股份有限公司 充當離子通道調節劑之稠合雜環化合物
US9546160B2 (en) 2011-05-12 2017-01-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
CN103687489A (zh) 2011-05-18 2014-03-26 埃南塔制药公司 制备5-氮杂螺[2.4]庚烷-6-甲酸及其衍生物的方法
NO3175985T3 (enExample) 2011-07-01 2018-04-28
TWI622583B (zh) 2011-07-01 2018-05-01 基利科學股份有限公司 作為離子通道調節劑之稠合雜環化合物
CA2841095A1 (en) 2011-07-09 2013-01-17 Sunshine Lake Pharma Co., Ltd. Spiro compounds as hepatitis c virus inhibitors
EP2741746A4 (en) * 2011-08-08 2014-12-31 Glaxosmithkline Llc CHEMICAL COMPOUNDS
WO2013030750A1 (en) 2011-09-01 2013-03-07 Lupin Limited Antiviral compounds
AP2014007575A0 (en) 2011-09-16 2012-04-30 Gilead Pharmasset Llc Methods for treating HCV
SMT201800470T1 (it) 2011-11-16 2018-11-09 Gilead Pharmasset Llc Imidazolilimidazoli condensati come composti antivirali
US9034832B2 (en) 2011-12-29 2015-05-19 Abbvie Inc. Solid compositions
US9326973B2 (en) 2012-01-13 2016-05-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CA2862755A1 (en) 2012-02-10 2013-08-15 Lupin Limited Antiviral compounds with a dibenzooxaheterocycle moiety
US20130309196A1 (en) 2012-05-16 2013-11-21 Gilead Sciences, Inc. Antiviral compounds
CN103420991B (zh) * 2012-05-17 2017-07-07 乳源东阳光药业有限公司 作为丙型肝炎抑制剂的吡咯烷衍生物及其在药物中的应用
TWI610916B (zh) 2012-08-03 2018-01-11 廣東東陽光藥業有限公司 作爲丙型肝炎抑制劑的橋環化合物及其在藥物中的應用
CN103848821B (zh) 2012-11-29 2016-10-12 广东东阳光药业有限公司 作为丙型肝炎抑制剂的螺环化合物、药物组合物及它们的用途
CN103848818B (zh) * 2012-11-29 2017-03-15 广东东阳光药业有限公司 作为丙型肝炎抑制剂的并环化合物、药物组合物及它们在药物中的应用
WO2014110687A1 (en) 2013-01-16 2014-07-24 Merck Sharp & Dohme Corp. Thiazolyl-substitued tetracyclic compounds and methods of use thereof for treatment of viral diseases
SG11201506021XA (en) 2013-01-31 2015-08-28 Gilead Pharmasset Llc Combination formulation of two antiviral compounds
RU2507201C1 (ru) 2013-02-07 2014-02-20 Александр Васильевич Иващенко Алкил [(s)-1-((s)-2-{5-[4-(4-{2-[(s)-1-((s)-2-метоксикарбониламино-3-метил-бутирил)-пирролидин-2-ил]-3н-имидазол-4-ил}-бута-1,3-диинил)-фенил]-1н-имидазол-2-ил}-пирролидин-1-карбонил)-2-метил-пропил]-карбамат нафталин-1,5-дисульфонат, фармацевтическая композиция, лекарственное средство, способ лечения вирусных заболеваний
US11484534B2 (en) 2013-03-14 2022-11-01 Abbvie Inc. Methods for treating HCV
US9717712B2 (en) 2013-07-02 2017-08-01 Bristol-Myers Squibb Company Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus
US20150023913A1 (en) 2013-07-02 2015-01-22 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
JP2016527232A (ja) 2013-07-17 2016-09-08 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｈｃｖの治療に使用するためのビフェニル誘導体を含む組み合わせ
JP2016529293A (ja) 2013-08-27 2016-09-23 ギリアド ファーマセット エルエルシー ２つの抗ウイルス化合物の組合せ製剤
WO2015103490A1 (en) 2014-01-03 2015-07-09 Abbvie, Inc. Solid antiviral dosage forms
CN104803989B (zh) 2014-01-23 2017-12-22 广东东阳光药业有限公司 作为丙型肝炎抑制剂的桥环化合物及其在药物中的应用
TWI721947B (zh) 2014-06-11 2021-03-21 美商基利法瑪席特有限責任公司 抗病毒化合物的固態形式
US10617675B2 (en) 2015-08-06 2020-04-14 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
JOP20170083B1 (ar) 2016-04-07 2022-03-14 Glaxosmithkline Ip Dev Ltd أميدات هتيروسيكلية مفيدة كمعدلات بروتين
WO2017181383A1 (en) 2016-04-21 2017-10-26 Merck Sharp & Dohme Corp. Hepatitis c virus inhibitors
MY196582A (en) 2018-02-13 2023-04-19 Gilead Sciences Inc PD-1/PD-L1 Inhibitors
WO2019204609A1 (en) 2018-04-19 2019-10-24 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
PT3820572T (pt) 2018-07-13 2023-11-10 Gilead Sciences Inc Inibidores pd-1/pd-l1
EP3870566A1 (en) 2018-10-24 2021-09-01 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
CN117460734A (zh) 2021-05-21 2024-01-26 吉利德科学公司 作为寨卡病毒抑制剂的五环衍生物
CN117321059A (zh) 2021-05-21 2023-12-29 吉利德科学公司 用于治疗寨卡病毒感染的四环化合物
IL309232A (en) 2021-06-14 2024-02-01 Scorpion Therapeutics Inc Urea derivatives which can be used to treat cancer

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3453315A (en) * 1965-06-23 1969-07-01 Roussel Uclaf 9-isopropylidenyl-9,10-dihydro-anthracene-10-carboxylic acid esters
US4371690A (en) * 1979-07-12 1983-02-01 E. I. Du Pont De Nemours And Company Heat-resistant rigid polymers from difunctional 9,10-dihydro-9,10-ethanoanthracenes
US20040082635A1 (en) * 2001-06-26 2004-04-29 Hiromasa Hashimoto Fused cyclic compounds and medicinal use thereof
WO2008021927A2 (en) * 2006-08-11 2008-02-21 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
CN101223153A (zh) * 2005-05-12 2008-07-16 默克勒有限公司 二苯并环庚烷化合物和含有这些化合物的药物

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH532608A (de) * 1969-12-17 1973-01-15 Ciba Geigy Ag Verfahren zur Herstellung von Bis-aroxazolyl-Verbindungen
CH553807A (de) * 1970-12-23 1974-09-13 Sandoz Ag Verfahren zur herstellung von dibenzthiophendioxidderivaten.
US3808206A (en) 1971-06-29 1974-04-30 Richardson Merrell Inc Bis-basic ketones of phenoxathiins and antiviral compositions thereof
US5288914A (en) 1984-08-27 1994-02-22 The Dow Chemical Company Poly(arylcyclobutenes)
US5288924A (en) * 1992-09-18 1994-02-22 Mobil Oil Corporation Process for starting up an olefin hydration reactor
US5807876A (en) 1996-04-23 1998-09-15 Vertex Pharmaceuticals Incorporated Inhibitors of IMPDH enzyme
US6054472A (en) 1996-04-23 2000-04-25 Vertex Pharmaceuticals, Incorporated Inhibitors of IMPDH enzyme
PL192628B1 (pl) 1996-04-23 2006-11-30 Vertex Pharma Pochodne mocznika, kompozycje farmaceutyczne i zastosowanie związku i kompozycji
DE69709671T2 (de) 1996-10-18 2002-08-22 Vertex Pharmaceuticals Inc., Cambridge Inhibitoren von serinproteasen, insbesondere von ns3-protease des hepatitis-c-virus
GB9623908D0 (en) 1996-11-18 1997-01-08 Hoffmann La Roche Amino acid derivatives
WO1998040381A1 (en) 1997-03-14 1998-09-17 Vertex Pharmaceuticals Incorporated Inhibitors of impdh enzyme
US6010848A (en) 1997-07-02 2000-01-04 Smithkline Beecham Corporation Screening methods using an atpase protein from hepatitis C virus
DE69827956T2 (de) 1997-08-11 2005-04-14 Boehringer Ingelheim (Canada) Ltd., Laval Peptidanaloga mit inhibitorischer wirkung auf hepatitis c
ES2244204T3 (es) 1998-07-27 2005-12-01 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Derivados de dicetoacidos como inhibidores de polimerasas.
US6323180B1 (en) 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
JP2002523371A (ja) 1998-08-21 2002-07-30 バイロファーマ・インコーポレイテッド ウイルス感染および関連疾患を治療または予防するための化合物、組成物および方法
EP1109580A4 (en) 1998-09-04 2004-05-26 Viropharma Inc METHOD FOR TREATING OR PREVENTING VIRAL INFECTIONS AND RELATED DISEASES
EP1115286A4 (en) 1998-09-25 2003-07-23 Viropharma Inc METHOD FOR TREATING AND PREVENTING VIRAL INFECTIONS AND DISEASES RELATED TO THEM
AU769383B2 (en) 1999-03-19 2004-01-22 Vertex Pharmaceuticals Incorporated Inhibitors of IMPDH enzyme
US6242602B1 (en) 1999-03-29 2001-06-05 Gentex Corporation One pot synthesis of 5,10-dihydrophenazine compounds and 5,10-substituted dihydrophenazines
US6566365B1 (en) 1999-11-04 2003-05-20 Biochem Pharma Inc. Method for the treatment of Flaviviridea viral infection using nucleoside analogues
US20040034041A1 (en) 2000-05-10 2004-02-19 Dashyant Dhanak Novel anti-infectives
US6448281B1 (en) 2000-07-06 2002-09-10 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
SV2003000617A (es) 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
EP1256628A3 (en) 2001-05-10 2003-03-19 Agouron Pharmaceuticals, Inc. Hepatitis c virus (hcv) ns5b rna polymerase and mutants thereof
JP2005500287A (ja) 2001-06-11 2005-01-06 シャイアー バイオケム インコーポレイテッド Ｆｌａｖｉｖｉｒｕｓ感染の処置または予防のための化合物および方法
PT1401825E (pt) 2001-06-11 2009-10-23 Virochem Pharma Inc Compostos e métodos para o tratamento ou para a prevenção de infecções com flavivírus
JP2003212846A (ja) * 2001-06-26 2003-07-30 Japan Tobacco Inc 縮合環化合物及びｃ型肝炎治療剤
WO2003007945A1 (en) 2001-07-20 2003-01-30 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
EP2335700A1 (en) 2001-07-25 2011-06-22 Boehringer Ingelheim (Canada) Ltd. Hepatitis C virus polymerase inhibitors with a heterobicylic structure
UA85366C2 (en) * 2001-07-25 2009-01-26 Бёрингер Ингельхайм (Канада) Лтд. Viral polymerase inhibitors
ES2289161T3 (es) 2001-11-02 2008-02-01 Glaxo Group Limited Derivados de 4-(heteroaril de 6 miembros)-acil pirrolidina como inhibidores de hcv.
JP2005511572A (ja) 2001-11-02 2005-04-28 グラクソ　グループ　リミテッド Ｈｃｖ阻害剤としてのアシルジヒドロピロール誘導体
EP1440070A1 (en) 2001-11-02 2004-07-28 Glaxo Group Limited 4-(5-membered)-heteroaryl acyl pyrrolidine derivatives as hcv inhibitors
RS51243B (sr) 2004-01-30 2010-12-31 Medivir Ab. Inhibitori ns-3 serina hcv proteaze
EP1804786A4 (en) * 2004-09-29 2008-01-02 Cytovia Inc SUBSTITUTED N-ARYL-9-OXO-9H-FLUORENE-1-CARBOXAMIDES AND ANALOGUES AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS
WO2006050496A1 (en) * 2004-11-02 2006-05-11 E.I. Dupont De Nemours And Company Substituted anthracenes and electronic devices containing the substituted anthracenes
US8143288B2 (en) 2005-06-06 2012-03-27 Bristol-Myers Squibb Company Inhibitors of HCV replication
US7745636B2 (en) 2006-08-11 2010-06-29 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7659270B2 (en) * 2006-08-11 2010-02-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7759495B2 (en) * 2006-08-11 2010-07-20 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7741347B2 (en) * 2007-05-17 2010-06-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7728027B2 (en) * 2007-08-08 2010-06-01 Bristol-Myers Squibb Company Process for synthesizing compounds useful for treating hepatitis C
US8629171B2 (en) * 2007-08-08 2014-01-14 Bristol-Myers Squibb Company Crystalline form of methyl ((1S)-1-((25)-2-(5-(4'-(2-((25)-1((2S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)-2-methylpropyl)carbamate dihydrochloride salt
US7704992B2 (en) * 2008-02-13 2010-04-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
JP5266786B2 (ja) * 2008-02-20 2013-08-21 富士ゼロックス株式会社 新規なフェノチアジン化合物
WO2010096462A1 (en) * 2009-02-17 2010-08-26 Enanta Pharmaceuticals, Inc Linked diimidazole derivatives
MX2011010132A (es) 2009-03-27 2011-10-14 Presidio Pharmaceuticals Inc Inhibidores de anillo fusionado de hepatitis c.

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3453315A (en) * 1965-06-23 1969-07-01 Roussel Uclaf 9-isopropylidenyl-9,10-dihydro-anthracene-10-carboxylic acid esters
US4371690A (en) * 1979-07-12 1983-02-01 E. I. Du Pont De Nemours And Company Heat-resistant rigid polymers from difunctional 9,10-dihydro-9,10-ethanoanthracenes
US20040082635A1 (en) * 2001-06-26 2004-04-29 Hiromasa Hashimoto Fused cyclic compounds and medicinal use thereof
CN101223153A (zh) * 2005-05-12 2008-07-16 默克勒有限公司 二苯并环庚烷化合物和含有这些化合物的药物
WO2008021927A2 (en) * 2006-08-11 2008-02-21 Bristol-Myers Squibb Company Hepatitis c virus inhibitors

Also Published As

Publication number Publication date
EA201190224A1 (ru) 2012-03-30
US20120040962A1 (en) 2012-02-16
SG174883A1 (en) 2011-11-28
CO6450600A2 (es) 2012-05-31
IL215202A0 (en) 2011-12-29
BRPI1012282A2 (pt) 2015-09-22
CN102427726A (zh) 2012-04-25
AR076164A1 (es) 2011-05-26
TW201038560A (en) 2010-11-01
JP2012522003A (ja) 2012-09-20
US9150554B2 (en) 2015-10-06
WO2010111534A1 (en) 2010-09-30
JP5735482B2 (ja) 2015-06-17
CL2011002377A1 (es) 2012-01-20
PE20120773A1 (es) 2012-07-19
MX2011010132A (es) 2011-10-14
EP2410843A1 (en) 2012-02-01
KR20110131312A (ko) 2011-12-06
ZA201107753B (en) 2012-07-25
EP2410843A4 (en) 2012-08-08
AU2010229795A1 (en) 2011-10-13
CA2755658A1 (en) 2010-09-30
HK1166446A1 (en) 2012-11-02

Similar Documents

Publication Publication Date Title
CN102427726B (zh) 丙型肝炎的稠环抑制剂
US8999967B2 (en) Tricyclic fused ring inhibitors of hepatitis C
CN102647909B (zh) Hcv ns5a的抑制剂
TWI494309B (zh) Ｃ型肝炎病毒（ｈｃｖ）nｓ５ａ抑制劑
US20120040977A1 (en) Inhibitors of hcv ns5a
EP2410841A1 (en) Substituted bicyclic hcv inhibitors
TW201201801A (en) Inhibitors of HCV NS5A protein
WO2012040389A2 (en) Substituted bicyclic hcv inhibitors
HK1166446B (en) Fused ring inhibitors of hepatitis c
HK1169277A (en) Inhibitors of hcv ns5a
HK1169277B (en) Inhibitors of hcv ns5a
HK1166445A (en) Inhibitors of hcv ns5a

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1166446

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1166446

Country of ref document: HK

CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20141008

Termination date: 20170325

CF01 Termination of patent right due to non-payment of annual fee